Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Hans M.G. Princen"'
Autor:
Tsai-Sang Dederichs, Peter Kohl, Katja Krebs, Clinton S. Robbins, Dennis Wolf, Bianca Dufner, Jiadai Zou, E.J. Pieterman, Timo Heidt, Christopher Starz, Rafael Kaeser, Natalie Hoppe, Peter Stachon, Tobias Boettler, Carmen Härdtner, Benoît Ho-Tin-Noé, Hans M.G. Princen, Florian Willecke, Andreas Zirlik, Diana Sharipova, Carolin A. Ehlert, Filip K. Swirski, Constantin von zur Mühlen, Alina Jander, Ingo Hilgendorf, Christoph Bode, Josef Madl, Simon Rauterberg, Jan Kornemann
Publikováno v:
Basic Research in Cardiology
Statins induce plaque regression characterized by reduced macrophage content in humans, but the underlying mechanisms remain speculative. Studying the translational APOE*3-Leiden.CETP mouse model with a humanized lipoprotein metabolism, we find that
Autor:
G. Stokman, M. Oudshoorn-Dickmann, Astrid Valles-Sanchez, C. Vendrell Tornero, Hans M.G. Princen, M. Golinska, N. Keijzer, M. De Haan, M. Van Veen, H. Wattimury, K. Van Rooijen, V. Zancanella, Ying Poi Liu
Publikováno v:
Web of Science
Autor:
Bianca Dufner, Dennis Wolf, Ingo Hilgendorf, Jan Kornemann, Natalie Hoppe, Peter Stachon, Andreas Zirlik, Hans M.G. Princen, C. Haerdtner, C. Bode, Katja Krebs
Publikováno v:
European Heart Journal. 40
Background Guidelines recommend cholesterol lowering for primary and secondary prevention of cardiovascular disease. While lipid lowering has been reported to induce plaque regression, the underlying mechanisms have remained speculative. Purpose We h
Autor:
Lars Verschuren, Jurjan Aman, Cornelis Kluft, Marianne G. Pouwer, Elsbet J. Pieterman, Martien P. M. Caspers, J. Wouter Jukema, Ricardo Garcia, Hans M.G. Princen
Publikováno v:
Frontiers in Cardiovascular Medicine
Frontiers in cardiovascular medicine, 5:55. Frontiers Media S.A.
Frontiers in Cardiovascular Medicine, Vol 5 (2018)
Pouwer, M G, Pieterman, E J, Verschuren, L, Caspers, M P M, Kluft, C, Garcia, R A, Aman, J, Jukema, J W & Princen, H M G 2018, ' The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model ', Frontiers in cardiovascular medicine, vol. 5, 55 . https://doi.org/10.3389/fcvm.2018.00055
Frontiers in Cardiovascular Medicine, 5(55)
Frontiers in Cardiovascular Medicine, 5
Frontiers in cardiovascular medicine, 5:55. Frontiers Media S.A.
Frontiers in Cardiovascular Medicine, Vol 5 (2018)
Pouwer, M G, Pieterman, E J, Verschuren, L, Caspers, M P M, Kluft, C, Garcia, R A, Aman, J, Jukema, J W & Princen, H M G 2018, ' The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model ', Frontiers in cardiovascular medicine, vol. 5, 55 . https://doi.org/10.3389/fcvm.2018.00055
Frontiers in Cardiovascular Medicine, 5(55)
Frontiers in Cardiovascular Medicine, 5
Treatment with the second and third generation BCR-ABL1 tyrosine kinase inhibitors (TKIs) increases cardiovascular risk in chronic myeloid leukemia (CML) patients. We investigated the vascular adverse effects of three generations of TKIs in a transla
Autor:
Gergana Galabova, José W.A. van der Hoorn, Marianne G. Pouwer, Hans M.G. Princen, Christine Landlinger, Elsbet J. Pieterman, J. Wouter Jukema, Guenther Staffler, Claudia Juno
Publikováno v:
European Heart Journal, 32, 38, 2499-2507
European Heart Journal, 38(32), 2499-U143
European Heart Journal, 38(32), 2499-U143
Aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target for the treatment of hypercholesterolaemia and atherosclerosis. PCSK9 binds to the low density lipoprotein receptor and enhances its degradation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46ac81cf34d192dafc084e7052c98244
http://resolver.tudelft.nl/uuid:31d3da74-88bf-479b-a516-90503763d0fe
http://resolver.tudelft.nl/uuid:31d3da74-88bf-479b-a516-90503763d0fe
Publikováno v:
Atherosclerosis Supplements. 32:8-9
Autor:
N. Worms, Viktoria Gusarova, Hans M.G. Princen, N. Keijzer, Marianne G. Pouwer, J. Gromada, Joop Jukema, E.J. Pieterman
Publikováno v:
Atherosclerosis. 287:e12
Autor:
Claudia Juno, Guenther Staffler, Joop Jukema, Andreas Mairhofer, José W.A. van der Hoorn, Achim Schneeberger, Gergana Galabova, Hans M.G. Princen, Elsbet J. Pieterman, Marianne G. Pouwer
Publikováno v:
Circulation. 132
Background: Elevated low density lipoprotein cholesterol (LDLc) is one of the major risk factors for premature cardiovascular diseases (CVD). Thus, therapeutic approaches aim at reducing LDLc. PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9) has
Autor:
Brendan Leighton, Margareta Behrendt, Ann-Cathrine Jönsson-Rylander, E.J. Pieterman, Wouter Jukema, A.M. van den Hoek, Hans M.G. Princen, Suvi E. Heinonen, Marianne G. Pouwer, Anne-Christine Andréasson
Publikováno v:
Atherosclerosis. 252:e226-e227
Autor:
M. Pouwer, Joop Jukema, Gergana Galabova, E.J. Pieterman, Guenther Staffler, Hans M.G. Princen, Christine Landlinger, J.W.A. van der Hoorn, Claudia Juno
Publikováno v:
Atherosclerosis. 252:e253-e254